Schering Moves Vicriviroc Phase III Program Forward In HIV
This article was originally published in The Pink Sheet Daily
Executive Summary
Company has initiated two Phase III studies of the CCR5 receptor antagonist in treatment-experienced HIV patients.
You may also be interested in...
Pfizer’s Selzentry Wins FDA Approval For HIV
First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.
Schering-Plough, Incyte Report Positive Mid-Stage Data For CCR5 Antagonists
Both Schering’s vicriviroc and Incyte’s INCB9471 CCR5 antagonist candidates to treat HIV beat placebo in Phase II trials.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.